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Abstract
The AXL receptor tyrosine kinase (RTK) is involved in partial epithelial-to-
mesenchymal transition (EMT) and inflammation – both main promoters of
renal fibrosis development. The study aim was to investigate the role of AXL
inhibition in kidney fibrosis due to unilateral ureteral obstruction (UUO).
Eight weeks old male C57BL/6 mice underwent UUO and were treated with
oral AXL inhibitor bemcentinib (n = 22), Angiotensin-converting enzyme
inhibitor (ACEI, n = 10), ACEI and bemcentinib (n = 10) or vehicle alone
(n = 22). Mice were sacrificed after 7 or 15 days and kidney tissues were ana-
lyzed by immunohistochemistry (IHC), western blot, ELISA, Sirius Red (SR)
staining, and hydroxyproline (Hyp) quantification. RNA was extracted from
frozen kidney tissues and sequenced on an Illumina HiSeq4000 platform. After
15 days the ligated bemcentinib-treated kidneys showed less fibrosis compared
to the ligated vehicle-treated kidneys in SR analyses and Hyp quantification.
Reduced IHC staining for Vimentin (VIM) and alpha smooth muscle actin
(aSMA), as well as reduced mRNA abundance of key regulators of fibrosis
such as transforming growth factor (Tgfb), matrix metalloproteinase 2
(Mmp2), Smad2, Smad4, myofibroblast activation (Aldh1a2, Crlf1), and EMT
(Snai1,2, Twist), in ligated bemcentinib-treated kidneys was compatible with
reduced (partial) EMT induction. Furthermore, less F4/80 positive cells, less
activity of pathways related to the immune system and lower abundance of
MCP1, MCP3, MCP5, and TARC in ligated bemcentinib-treated kidneys was
compatible with reduction in inflammatory infiltrates by bemcentinib treat-
ment. The AXL RTK pathway represents a promising target for pharmacologic
therapy of kidney fibrosis.
Introduction
Chronic kidney diseases (CKD) are on the rise in many
parts of the world, representing a global public health
issue (Eckardt et al. 2013; USRDS, 2016). The worldwide
prevalence of CKD is around 13% for stages 1–5 and
10% for stages 3–5 and is expected to rise due to
increased prevalence of obesity, type 2 diabetes mellitus,
hypertension, and also longevity (Jha et al. 2013; Mills
et al. 2015; Hill et al. 2016). The age standardized death
rate for CKD has increased by more than 30% between
1990 and 2013 and this trend is expected to continue
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(Eckardt et al. 2013; GBD, 2015). High mortality of CKD
has been attributed to accelerated vascular calcification
and cardiovascular diseases (Go et al. 2004; Stenvinkel
2010). The burden on the health care system increases
with CKD severity; foremost end stage renal disease is
costly as a result of long-term dialysis and transplantation
(Honeycutt et al. 2013).
Kidney fibrosis is the morphological correlate of pro-
gressive CKD and is characterized by the accumulation of
myofibroblasts with subsequently substantial extracellular
matrix (ECM) deposition, inflammation, tubular epithe-
lial cell loss, and microvascular rarefaction (Kuncio et al.
1991; Zeisberg and Neilson 2010). Activated myofibrob-
lasts are one of the key cells in the pathogenesis of fibro-
sis, and it was initially suggested that they are derived
mainly from tubular epithelial cells through epithelial-to-
mesenchymal transition (EMT) (Iwano et al. 2002).
Recent lineage tracing experiment reported that prolifera-
tion of tissue resident fibroblasts, differentiation of bone
marrow precursors and endothelial to mesenchymal tran-
sition all together form the majority of the myofibroblast
pool in kidney fibrosis, while less than 5% are directly
derived from the renal tubular cells by EMT (LeBleu et al.
2013). Accordingly, an incomplete, “partial” EMT of the
renal tubular epithelial cells has been suggested to pro-
mote fibrosis development through cell-cycle arrest and
paracrine secretion of growth factors and cytokines –
including TGF-b – that trigger the activation of myofi-
broblasts and induce inflammation (Ovadya and Krizha-
novsky 2015; Lovisa et al. 2016; Nieto et al. 2016). Key
transcription factors driving partial EMT of tubular
epithelial cells are SNAI1/2, TWIST, and STAT1 (Lee
et al. 2014; Grande et al. 2015; Lovisa et al. 2015). In
addition, the inflammatory response to kidney injury,
although aimed to preserve the integrity of the tissue at
the initial stages of CKD, provides a reservoir of cytokines
and enzymes that promote the ongoing fibrosis process
(Lovisa et al. 2016).
CKD progression can be attenuated in its early phases
by control of blood pressure, proteinuria, and therapy
addressing the underlying disease, such as diabetes melli-
tus, hypertension or glomerulonephritis. Due to high
morbidity and mortality related to kidney diseases, there
is a need for new therapeutic strategies that target the
fibrosis-related mechanisms in the kidney. The transmem-
brane AXL receptor belongs to the TAM family of recep-
tor tyrosine kinases (RTK) together with MERTK and
TYRO3 and is an important mediator of inflammation, as
well as EMT in malignancies (Korshunov 2012; Axelrod
and Pienta 2014; Feneyrolles et al. 2014; Dransfield and
Farnworth 2016). In accordance, AXL RTK inhibition
blocks tumorigenicity and reduces aggressiveness of solid
tumors (Janning et al. 2015; Yu et al. 2015). AXL RTK is
thus an important therapeutic target in cancer and the
small molecule bemcentinib, a selective AXL RTK inhibi-
tor (formerly called BGB324), is currently in phase II
clinical trials for e.g. AML (NCT02488408), NSCLC
(NCT02424617; NCT02922777), melanoma (NCT028
72259) and breast cancer (NCT03184558) (ClinicalTrials.-
gov, 2018).
In solid organ fibrosis, AXL RTK has been studied in
experimental liver, lung, and renal fibrosis (Barcena et al.
2015; Espindola et al. 2018; Zhen et al. 2018). However,
the effect of AXL RTK inhibition in kidney fibrosis
remains to be a relatively understudied area (Batchu et al.
2013; Hyde et al. 2014). Unilateral ureteral obstruction
(UUO) represents an established animal model for renal
fibrosis development that also involves partial EMT as a
main driver (Grande et al. 2015; Lovisa et al. 2015).
Within 1 day after obstruction, reduction in renal perfu-
sion occurs, which is followed by hydronephrosis and
fibrosis development within a few days, and loss and flat-
tening of the cortex within 1–2 weeks. The contralateral
nonligated kidney remains histologically normal and can
therefore serve as a control (Vaughan et al. 2004; Cheva-
lier et al. 2009).
The hypothesis of this study was that AXL RTK is
involved in fibrosis development in UUO and that inhibi-
tion of AXL RTK with the selective small molecule bem-
centinib leads to the reduction in fibrosis development in
UUO.
Methods
Animals
Eight to nine-week-old male C57Bl/6JOlaHSD mice were
obtained from Envigo (Horst, The Netherlands). All ani-
mals were kept in the local animal facility of the Depart-
ment of Biomedicine at the University of Bergen,
Norway. The experiments were conducted in accordance
with the guidelines and approval of the Norwegian Food
Safety authority (Approval numbers: 16/116548 and 17/
129461).
Unilateral ureteral obstruction
All surgical procedures were performed under isoflurane
anaesthesia (Isoflurane, Baxter, Oslo, Norway. ATC-nr:
N01A B06). The operation site was shaved with an elec-
tric shaver, disinfected, and the left ureter was identified
through a subcostal incision and obstructed using a silk
ligature at the level of the lower pole of the kidney. Peri-
toneum and muscles were sewn with Prolene 3-0 (Ethi-
con, polypropylen, Summerville, NJ USA) and the skin
was clipped with “ez clip wound closures” (Stoelting,
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Wood Dale, USA). Mice were treated with buprenorphine
(Temgesic, Indivior, ATC-nr: N02A E01) 0.1 mg/kg after
the operation (Tveitaras et al. 2015).
Experimental setup
The experimental setup and treatment groups are illus-
trated in Figure 1. Animals were divided in groups treated
with bemcentinib, [(1-(6,7-dihydro-5H-benzo[6,7]cyclo-
hepta[1,2-c]pyridazin-3-yl)-N3-((7-pyrrolidin-1-yl)-6,7,8,9
-tetrahydro-5H-benzo[7]annulene-2-yl)-1H-1,2,4-triazole-
3,5-diamine)], its solvent Vehicle (0.5% hydroxylpropyl-
methylcellulose in 0.1% tween 80), Angiotensin-converting
enzyme inhibitor (ACEI, Enalapril maleate salt, Sigma-
Aldrich, E6888) or ACEI plus bemcentinib. Bemcentinib
was administered by oral gavage at a dose of 50 mg/kg
(10 mL/kg) twice daily beginning 1 day before or 3 days
after operation. The ACEI was dissolved in Methanol and
supplied in the drinking water at 100 mg/L and a fresh
solution was prepared every third day (Moridaira et al.
2003).
Sacrifice of mice and sample collection
Animals were sacrificed on day 7 or day 15 after the oper-
ation. Mice were anesthetized with isoflurane, the abdom-
inal aorta was dissected and cannulated in order to
perfuse the organs with ice-cold PBS (Tveitaras et al.
2015). The kidneys were then removed and cut in trans-
verse slices that were either snap frozen in RNAlater
(RNA Stabilization agent; Qiagen, Venlo, the Netherlands,
catalog number: AM7020) and stored at 80°C or fixed
in 4% formaldehyde to be processed and embedded in
paraffin according to standard procedures at the Institute
of Pathology, Haukeland University Hospital, Bergen,
Norway. Blood was collected using heart puncture at time
of sacrifice. Serum creatinine levels were measured by
Bevital AS, Bergen, Norway, using established HPLC-MS/
MS methodology (Midttun et al. 2013).
Immunohistochemistry and Sirius Red
staining
FFPE sections (3 lm) from the ligated and the nonligated
kidneys were deparaffinized in xylene and rehydrated in
decreasing concentrations of ethanol. Sections subjected
to Sirius Red (SR) staining were incubated with a solu-
tion of 0.1% SR F3B (BDH Laboratory supplies, catalog
number: 34149) in saturated aqueous picric acid for
30 min. Sections for immunohistochemistry were sub-
jected to microwave heat (pH 9.0 or pH 6.0 target retrie-
val buffer, Dako) or enzyme-induced epitope retrieval as
shown in Table 1, followed by 10 min incubation with
Peroxidase block (Dako) to quench endogenous peroxi-
dase activity. Blocking of unspecific binding sites was
achieved by incubating the section with 10% normal goat
serum (Dako) or Avidin/Biotin block (Vectorlabs)
depending on the detection method used. Primary anti-
bodies were diluted in antibody diluent with background
reducing agent (Dako). Dilutions, incubation times, and
retrieval methods employed for each reaction are listed in
Table 1. Labeled polymer-Horseradish peroxidase conju-
gated to goat antimouse or antirabbit immunoglobulins
(Envision+ system, Dako) was used to detect
Figure 1. Experiment setup. Experiment setup of unilateral ureteral obstruction (UUO) in male C57Bl/6 mice. Pretreatment of C57Bl/6 mice
with either bemcentinib, ACE inhibitor (ACEI), bemcentinib plus ACEI or vehicle was started 1 day before the operation. Mice were subjected
to UUO at day 0. Subsequently, mice were sacrificed on day 7 (n = 6 for bemcentinib, n = 6 for vehicle-treated mice) or 15 (n = 16 for
bemcentinib, n = 10 for ACEI, and bemcentinib plus ACEI and n = 16 for vehicle-treated mice) after the operation.
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immunoreactivity of anti-Vimentin (VIM), anti-alpha
Smooth muscle actin (aSMA), anti-N-cadherin (CDH2)
and anti-Twist antibodies. Tissue bound anti-AXL anti-
body was detected using 30 min incubation with rabbit
anti-goat IgG (1:1000, SouthernBiotech), followed by
incubation with Envision+ polymer. Anti-F4/80 antibody
was detected using 30 min incubation with biotinylated
goat anti-rat IgG (1:300, Vectorlabs), followed by Vectas-
tain ABC-HRP reagent (Vectorlabs). All immunoreactions
were visualized using 3,30-diaminobenzidine (DAB,
Dako), counterstained with Hematoxylin (Dako), dehy-
drated and cover-slipped using nonaqueous mounting
medium. All reagents and kits were used by following the
manufacturer‘s instructions.
Quantification of immunohistochemistry
and Sirius Red stainings
Stained slides were scanned in ScanScopeTM system (Ape-
rio, Vista, California, USA) with a resolution of 0.23 lm
per pixel, and the generated digital slides were viewed in
Imagescope 12 (Leica Biosystems, Nussloch, Germany).
Quantification of SR and IHC stainings were carried out
using the color deconvolution algorithm version 9 (Ape-
rio), and the red, green, and blue (RGB) values for SR or
DAB were obtained as described elsewhere (Ruifrok and
Johnston 2001; Osman et al. 2013; Rosa et al. 2013). The
obtained percentages of positive pixels were compared
between different treatment groups.
Scoring of cortical tissue loss
Central transversal sections of the kidney were stained
with PAS. The sections were reviewed by two of the
authors (S. L. and J. B.) in a blinded manner. Cortex
thickness and pelvis dilatation were semiquantitatively
scored according to a visual grading scale from 0 to 4,
where 0 corresponds to normal cortex thickness and
unremarkable pelvis and 4 corresponds to maximal cortex
thinning and pelvis dilatation (O’Neill 2000).
Quantification of collagen deposition by
hydroxyproline measurement
The colorimetric QuickZyme total collagen assay was
utilized for quantification of collagen deposition by
hydroxyproline (Hyp) measurement (QuickZyme Bio-
sciences, Leiden, The Netherlands, catalog number:
QZBtotcol1). Aliquots of 10–25 mg of snap frozen mouse
renal tissues were first hydrolyzed in 6 mol/L HCl for
20 h at 95°C. The lysates were diluted to 4 mol/L HCl
and then added in triplicates to a 96-well plate. Assay
buffer and detection reagent were then added and the
plate was incubated for 60 min at 60°C and read at
570 nm on a spectrophotometer. Quantity of total pro-
teins was determined by using the QuickZyme total pro-
tein assay (QuickZyme, catalog number: QZBtotprot1).
Following the addition of assay buffer and a color
reagent, the assay plate was incubated at 85°C for 60 min
and then read at 570 nm on a spectrophotometer. Read-
outs of the collagen assay were normalized to total pro-
tein contents of the tissue samples.
Western blot
Protein extraction from mouse kidney tissues was
achieved by using RIPA buffer (Sigma-Aldrich, catalog
number: R0278) with the addition of complete protease
inhibitor (Roche, catalog number: 4693116001) and phos-
phatase inhibitor cocktail (Sigma-Aldrich, catalog num-
ber: P5726). Protein concentration was determined using
Pierce BCA Protein Assay Kit (Thermo Scientific, catalog
number: 23225). Proteins were separated in Bolt 4–12%
Bis-Tris Plus electrophoresis gels and transferred to nitro-
cellulose membranes using iBlot 2 System. Membranes
were blocked with 5% BSA in PBS containing 0.1%
Tween-20 and then incubated overnight with goat anti-
mouse AXL (R&D, catalog number: AF854), or with rab-
bit anti-SNAIL+SLUG (Abcam, ab180714). SeeBlue Plus2
Pre-stained Protein Standard (Invitrogen, LC5925) was
used to visualize protein molecular weight. The blots were
Table 1. Antibodies used in immunohistochemistry.
Antibody Company Catalog number Epitope retrieval Dilution Incubation
Monoclonal rabbit anti-VIM Abcam ab92547 pH 9 1:3000 1 h
Purified rat anti- F4/80 BioRad MCA497GA Proteinase K 1:300 Overnight
Polyclonal goat anti- AXL R & D systems AF854 pH 9 1:1000 1 h
Monoclonal mouse anti-aSMA Dako M0851 No retrieval 1:200 30 min
Monoclonal mouse anti-CDH2 Abcam ab98952 pH 6 1:1000 1 h
Monoclonal mouse anti-TWIST LSBio SAB4504605 pH 6 1:2000 1 h
Antibodies against Vimentin (VIM), F4/80, AXL, alpha Smooth muscle actin (aSMA), C-cadherin (CDH2), and TWIST used for immunohisto-
chemical stainings in this study, including their provenance, mode of epitope retrieval, dilution, and incubation duration.
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washed three times with a wash buffer (PBS, 0.1%
Tween-20) and then incubated for 1 h either with rabbit
anti-goat (Southern Biotech, catalog number: 6164-01),
or goat anti-rabbit (Abcam, ab205718) secondary HRP-
linked antibodies for detection of AXL and SNAIL,
respectively. The blots were washed again and developed
using Pierce ECL Plus Western blotting substrate
(Thermo Fisher). Chemo-luminescence signals were
assessed using Syngene G:Box camera and GeneSys soft-
ware (Cambridge, UK). Densitometry analysis was per-
formed using the ImageJ.
Quantification of chemokines by multiplex
bead immunoassays
Chemokine levels were analyzed using a multiplex fluores-
cent bead-based immunoassay (Bio-Plex Pro Mouse Che-
mokine Assay, Bio-Rad Laboratories, catalog number:
12002231 and Y60000CMCZ). The Bio-Plex 200 System
processed by Luminex was used, including microplate
platform and Bio-Plex Manager 6 software. The analysis
was done according to the manufacturer’s recommenda-
tions based on the Luminex xMAP technology. The
amount of protein in each sample was extrapolated and
compared with the standard curve ranges with concentra-
tions reported in pg/mL (Houser 2012).
RNA extraction and mRNA sequencing
For RNA extraction from frozen murine tissues, we used
the RNeasy mini kit (Qiagen, catalog number: 74104). To
determine the quality of extracted RNA, we used the Agi-
lent 2100 BioAnalyzer and RNA 6000 Nano total RNA kit
(Agilent Technologies, catalog number: 5067-1511).
Sequencing libraries of murine tissues were prepared
using the TruSeq stranded mRNA library preparation kit
(Illumina, USA) and sequenced on an Illumina
HiSeq4000 platform at the Genomics Core Facility at the
Department of Clinical Medicine at Haukeland University
Hospital, Bergen, Norway.
Analysis of mRNA sequencing data
Reads of murine mRNA were aligned to GRCm38, M13
Gencode release using HISAT2 2.0.5 (Kim et al. 2015).
Aligned reads present within adequate GENCODE gene
annotation regions (Harrow et al. 2006) were counted
using featureCounts (Liao et al. 2014). Count data were
analyzed using the LIMMA package in R bioconductor
(https://www.bioconductor.org/packages/release/bioc/
html/limma.html) (Ritchie et al. 2015). Preprocessing of
count data included log2 transformation and scaling to
the library size to obtain log2 cpm values (log2 of counts
per million). Voom was applied to estimate nonparamet-
rically the mean-variance trend of the logged read counts
and to use this mean-variance relationship to predict the
variance of each log2cpm value (Law et al. 2014). Further
model fitting was performed as outlined (Ritchie et al.
2015). Various contrasts were then applied to obtain sta-
tistically significant expression changes. An arbitrary cut-
off (Benjamini-Hochberg adjusted P-value of 0.05 and a
minimum fold change of 1.5) was applied as criteria for
significance. Additional computation and data visualiza-
tion was performed using the software JMP Genomics
(v.8.2, www.sas.com), and Graphpad Prism v. 7
(www.graphpad.com). The “perturbation score” of mur-
ine mRNA expression results was calculated as follows:
for each sample, normalized log2cpm values were stan-
dardized to the average normalized log2cpm of the nonli-
gated samples. Ratios smaller than 1 were inversed, so
that values for under- and over representation would
contribute equally to the score and not balance each
other out. The average ratio was calculated for all genes
by sample, resulting in the perturbation score for each
sample. The list of “random genes” was generated within
JMP Genomics. The list of metzincins and related genes
(MARGS) was taken from our previous publication
(Marti et al. 2014). The list of macrophage-related genes
were taken from (Mosser and Edwards 2008). All other
gene lists were extracted from SABiosciences (http://gnc
pro.sabiosciences.com/gncpro/gncpro.php). The gene lists
are presented in the Table S1.
The sequencing data are available in the repository
Gene Expression Omnibus https://www.ncbi.nlm.nih.
gov/geo/query/acc.cgi?acc=GSE123674.
Gene ontology and pathway analysis
Significantly up- and down-regulated genes were analyzed
for enrichment of gene ontology (GO) terms (including
biological processes in particular) and KEGG pathway by
using PantherDB (www.pantherdb.org) (Mi et al. 2017).
In the results, we mainly focused on “biological pro-
cesses” because these are the most widely used for GO
analysis. False Discovery Rate (FDR) values lower than
0.05 were considered significant.
Statistics
Results are presented as mean  standard deviation. Pair-
wise comparisons between the ligated and contralateral
nonligated kidneys were performed by paired sample t-
test. The unpaired t-test was used to compare differences
between two groups, such as mRNA abundance in ligated
bemcentinib-treated or vehicle-treated kidneys. For multi-
ple group comparisons such as in SR or IHC staining and
ª 2019 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
The Physiological Society and the American Physiological Society.
2019 | Vol. 7 | Iss. 10 | e14091
Page 5
L. Landolt et al. AXL Targeting in UUO
hydroxyproline content measurement analyses, one-way
ANOVA was performed, always followed by post hoc
analysis with Bonferroni correction. Values of P ≤ 0.05
were regarded as significant. P values were marked with *
(≤0.05), ** (≤0.01), *** (≤0.001), and **** (≤0.0001).
All analyses were performed in Statistical Package for
Social Sciences (SPSS, Version 25, IBM Analytics).
Results
Ureteral ligation induces fibrosis,
inflammation, and up-regulation of AXL
To characterize the degree of EMT development and AXL
expression of the UUO model, we first analyzed the effect
of ureteral obstruction in terms of fibrosis, EMT, and
inflammation by pairwise comparison of ligated and con-
tralateral nonligated kidneys harvested from the vehicle-
treated group at day 15 (n = 16). Histological examina-
tion identified visible tubulointerstitial fibrosis and tubu-
lar atrophy in the ligated kidneys (Fig. 2A and B).
Quantification of the percentage of total positive pixels in
SR stained kidney sections (Fig. 2D and E) revealed a sig-
nificantly higher amount of collagen deposition in the
ligated kidneys (mean percentage (%) of positive pixels
14.5  7.4% standard deviation (SD) as compared to the
contralateral nonligated kidneys (2.5%  2.4%, paired
samples t-test, P-value < 0.001). These findings were fur-
ther supported by colorimetric quantification of Hyp in
kidney lysates of the same mice where significantly higher
signals were detected from the ligated kidneys
(7.76  2.39 lg Hyp/mg total protein) in comparison to
the contralateral kidney (2.37  0.59 lg Hyp/mg total
protein, P-value < 0.001). Moreover, IHC staining for
aSMA and VIM (Fig. 2G–L) also showed more staining
in ligated compared to nonligated kidneys; an evidence of
higher proliferation and activation of myofibroblasts. The
mean percentage of positive pixels for VIM was found to
be 56.5  5.7% in the ligated kidneys, while contralateral
kidneys scored 18.69  1.85% (P-value < 0.001). In the
case of aSMA, the difference was also found to be statisti-
cally significant (P-value = 0.006), with ligated kidneys
having 70.13  11.65% compared to 25.2  7.68% for
the nonligated kidneys.
Expression of EMT-related markers was also found to
be increased by ureteral obstruction, and AXL staining was
detected in the intertubular interstitial cells, sporadically
apical in the tubular epithelial cells of atrophic tubules and
in parietal cells of the Bowman0s capsule in glomeruli
(Fig. 2Q and R). Additionally, higher amounts of AXL
and SNAIL proteins were detected in the lysates of ligated
kidneys in comparison to nonligated in western blot
(Fig. 3A, B, E and G). Ligated vehicle-treated kidneys
showed higher expression of TWIST (percentage of posi-
tive pixels 70.7  4.4%) as compared to the contralateral
kidney (52.6  3.8%, P = 0.002) by IHC (Fig. 3I and K).
No statistically significant difference in CDH2 expression
was detected by quantification of IHC (Fig. 3J and L).
Taken together, these findings indicate induction of a par-
tial EMT program by kidney ligation as evident by altered
expression of SNAIL, TWIST, AXL but not CDH2.
Ligated kidneys were found to be highly infiltrated by
F4/80 positive cells (30.8  12.4% positive pixels) as
compared to their nonligated counterparts (4.9  1.8%,
P = 0.008). Additionally, analysis of inflammatory cytoki-
nes in kidney tissue lysates by ELISA showed significantly
elevated levels of several inflammatory cytokines in the
ligated kidneys (Table 2). Moreover, fibroblast growth
factor (FGF) was found to be higher in lysates from
ligated kidneys (4590  906.5 pg/mL) in comparison to
670  68.4 pg/mL in the contralateral kidneys (Table 2).
Treatment with bemcentinib reduces
fibrosis development in obstructed kidneys
Differences in fibrosis development between ligated kid-
neys from bemcentinib and vehicle-treated mice were not
detectable after 7 days of obstruction, and renal tissues
only displayed a low grade of fibrosis in SR staining as
measured by Aperio (6.2  2.9% positive pixels in ligated
bemcentinib-treated and 6.9  4.3% in ligated vehicle-
treated kidneys, P = 0.74) (Fig. 4A). After 15 days, the
amount of fibrotic tissue as measured by SR staining
remained low in the ligated bemcentinib-treated kidneys
(mean 6.3  3.3%), but was significantly increased in the
ligated vehicle-treated group (14.7  6.1% SD, P < 0.001,
one-way ANOVA) (Figs. 2E, F and 4B). Treatment with
ACEI did not result in a significant reduction in fibrosis
development in the ligated kidneys compared to the
ligated vehicle-treated controls (11.9  4.4% in ligated
ACEI-treated kidneys). However, bemcentinib treatment
resulted in less fibrosis development as measured by SR
staining in ligated kidneys as compared to ligated ACEI-
treated kidneys (P = 0.026, one-way ANOVA). Combined
treatment with bemcentinib plus ACEI did not show an
additive effect on fibrosis development in ligated kidneys
compared to bemcentinib treatment alone (7.9  3.2% in
ligated bemcentinib plus ACEI-treated kidneys) (Fig. 4B).
In accordance with SR staining, significantly less Hyp
content was measured in the ligated bemcentinib-treated
compared to the ligated vehicle-treated kidneys after
15 days (16.8 lg Hyp per mg total protein (lg/
mg)  4.6 lg/mg SD in ligated bemcentinib-treated kid-
neys and 24.2  7.9 lg/mg in ligated vehicle-treated kid-
neys, P = 0.014, one-way ANOVA). Bemcentinib showed
a tendency to less fibrosis development in ligated kidneys
2019 | Vol. 7 | Iss. 10 | e14091
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compared to the ACEI-treated group as measured by Hyp
quantification, but the difference was not statistically sig-
nificant. However, ACEI had no significant effect on
fibrosis development in ligated kidneys compared to vehi-
cle treatment (18.6  6.2 lg/mg in the ligated ACEI-trea-
ted kidneys, P = 0.291 in one-way). Again, bemcentinib
plus ACEI did not have an additive effect (Fig. 4C). Sham
operated mice did not show any sign of fibrosis or other
renal damage.
Semiquantitative scoring of the cortex thickness and
pelvis dilatation in ligated kidneys, as described in Meth-
ods, showed a lower score for bemcentinib-treated ligated
kidneys (Score 1.7  0.8 SD) as compared to vehicle
treatment (Score 2.8  1.2 SD, n = 16, P = 0.015). This
corresponds to preservation of more cortical tissue as a
result of bemcentinib therapy.
Taken together, these findings confirm less fibrosis
development through inhibition of AXL RTK.
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Figure 2. Representative histological images of kidney tissues harvested from male C57Bl/6 mice after 15 days of ureteral obstruction.
Formalin fixed paraffin embedded sections from nonligated (left column), ligated vehicle-treated (middle column) or ligated bemcentinib-treated
kidneys (right column), stained with PAS (A–C), Sirius Red (SR, D–F), or stained by immunohistochemistry (brown) for alpha Smooth muscle
actin (aSMA, G–J), Vimentin (VIM, K–M), F4/80 (N–P) or AXL (Q–S). Unilateral ureteral obstruction leads to tubulointerstitial fibrosis and tubular
atrophy in the ligated kidney compared to the nonligated kidney as seen in the Periodic Acid Schiff staining (PAS, A, B). Counterstaining with
hematoxylin. Scale bar is 50 lm.
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Figure 3. Protein levels of EMT-related markers in UUO and the effect of Bemcentinib treatment. Comparison of AXL (A) and SNAIL (B)
concentrations in ligated (L) and nonligated (NL) kidney lysates from vehicle-treated mice after 15 days of obstruction. AXL (C) and SNAIL (D)
abundance in ligated kidneys from bemcentinib (Bem-L) and vehicle (Veh-L)-treated kidney lysates. Quantification of the WB bands intensity (E–
H). Immunohistochmical staining of TWIST (K) and N-cadherin (L) in nonligated (left), ligated vehicle-treated (middle) or ligated bemcentinib
kidneys (right).
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Attenuated EMT and myofibroblast
activation in ligated kidneys by bemcentinib
treatment
After 15 days of obstruction, percentage of positive pixels
for IHC of VIM was significantly lower in the ligated bem-
centinib-treated compared to the ligated vehicle-treated
kidneys (46.3  10.0% in ligated bemcentinib-treated,
61.0  7.8% in ligated vehicle-treated kidneys, P = 0.0002,
one-way ANOVA). Percentage of positive pixels for IHC of
aSMA was significantly lower in the ligated bemcentinib-
treated compared to the ligated vehicle-treated kidneys
(58.7  10.6% SD in ligated bemcentinib-treated,
75.7  9.0% in ligated vehicle-treated kidneys,
P = 0.00016, one-way ANOVA) (Figs. 2G, M and 4D, E).
Bemcentinib treatment lead to significantly less VIM and
aSMA staining in ligated kidneys compared to the ligated
vehicle-treated controls, but combined treatment with
ACEI did not have an additive effect (Fig. 4D and E).
Statistically significant difference between bemcentinib-
and vehicle-treated ligated kidneys was detected by quan-
tification of IHC TWIST (Bemcentinib 63.7  4.3%,
71.1  3.6% Vehicle, P = 0.003, Fig. 3I and K). On the
other hand, bemcentinib treatment did not have a signifi-
cant effect in the expression of CDH2 as measured by
IHC quantification (Fig. 3J and L).
Analysis of mRNA sequencing data showed that bem-
centinib treatment resulted in down-regulation of
mRNA abundances of several key genes involved in
fibrosis and EMT development in the ligated kidneys as
compared to the vehicle-treated group. A selection of
particularly relevant genes is provided in Table 3A.
Notably, the key EMT inducing transcription factors
Snai1/2, Twist, and Stat1 as well as collagens (e.g. colla-
gen III and IV chains), Tgfb1, including Tgfbr1/2, Akt3,
Elastin, and Smad2/4, were down-regulated as a conse-
quence of bemcentinib treatment. Accordingly, thera-
peutic intervention also led to a reduction in Axl
expression on the mRNA level (Table 3A). The lower
abundance of SNAIL was confirmed on the protein
level in quantified western blot bands (P = 0.002,
Fig. 3H). AXL showed a tendency to lower protein
abundance in this analysis but with borderline statistical
significance (Fig. 3F). Noteworthy, no significant down-
Table 2. Cytokines, chemokines, and proteins as measured by ELISA in ligated and nonligated kidneys 15 days after obstruction.
Chemokine Kidney Mean n SD P-value
Eotoxin2 (CCL24) Ligated 2770.4780 5 380.88481 0.016
Nonligated 1484.1840 5 383.64506
Fractalkine (CX3CL1) Ligated 524.9280 5 108.32174 0.029
Nonligated 309.2780 5 44.58575
KC (CXCL1) Ligated 52.4360 5 10.90941 0.003
Nonligated 32.6000 5 9.16972
MCP1 (CCL2) Ligated 460.5320 5 94.53758 0.000
Nonligated 235.1500 5 46.73821
MCP3 (CCL7) Ligated 106.0100 5 13.11334 0.002
Nonligated 22.8660 5 4.54817
MIP2 (CXCL2) Ligated 677.6900 5 66.70261 0.000
Nonligated 25.9520 5 6.93674
TARC (CCL17) Ligated 164.9520 5 35.77862 0.004
Nonligated 82.7700 5 5.96584
MCP5 (CCL 12) Ligated 527.6900 5 170.31400 0.002
Nonligated 24.7700 5 9.47600
IL-8 Ligated 100.1667 6 29.47146 0.000
Nonligated 670.6667 6 68.40955
FGF Ligated 4590.5000 6 906.44928 0.000
Nonligated 133.3333 6 32.92820
M-CSF Ligated 267.0000 6 31.89984 0.000
Nonligated 33.6667 6 7.14609
VEGF Ligated 33.8333 6 6.99762 0.000
Nonligated 363.0000 6 52.86965
IL-5 Ligated 6.0000 6 1.41421 0.000
Nonligated 37.8333 6 4.62241
G-CSF Ligated 15.1667 6 4.62241 0.001
Nonligated 1.8333 6 0.40825
Differences in the mean protein concentration (pg/mL) were investigated for statistical significance by paired sample t-test.
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Figure 4. Quantification of Sirius Red staining, immunohistochemistry and hydroxyproline content. Bar charts representing the mean
percentage of positive pixels of Sirius Red (SR) staining after 7 days (A) and 15 days (B), the mean percentages of positive pixels of
immunohistochemistry for Vimentin (D), aSMA (E) and F4/80 (F), and hydroxyproline (Hyp, C) content quantification of ligated (L) and
nonligated (NL) kidneys treated with vehicle, bemcentinib, Angiotensin-converting enzyme inhibitor (ACEI) or bemcentinib + ACEI (B) after
15 days of obstruction. Error bars represent standard deviation.
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regulation of CDH2 by bemcentinib treatment was
detected on the mRNA level (Table 3A). Expression of
key myofibroblast-associated genes (summarized in
Table 3B) such as Aldh1a2 and Crlf1 were also found
to be down-regulated as an effect of bemcentinib treat-
ment supporting a decreased activation of these cells
(Grgic et al. 2014). These findings are compatible with
attenuation of fibrosis progression through inhibition of
EMT development and fibroblast activation following
bemcentinib treatment.
Fibrosis-related genes are differentially
expressed following bemcentinib treatment
We evaluated and compared the effect of bemcentinib
treatment over 15 days on gene expression in ligated
Table 3. Gene expression changes in ligated bemcentinib-treated compared to ligated vehicle-treated kidneys after 15 days. (A) Fibrosis and
EMT-related genes, and (B) Myofibroblast associated genes (Grgic et al. 2014).
ENSEMBL ID Symbol Fold change AveExpr P.Value adj.P.Val
(A)
ENSMUSG00000024563 SMAD2 1.12 5.56 0.019 0.044
ENSMUSG00000024515 SMAD4 1.13 6.13 0.006 0.017
ENSMUSG00000017466 TIMP2 1.17 7.82 0.040 0.079
ENSMUSG00000032440 TGFBR2 1.19 7.99 0.001 0.003
ENSMUSG00000031273 COL4A6 1.20 3.02 0.013 0.033
ENSMUSG00000002603 TGFB1 1.24 5.49 0.007 0.018
ENSMUSG00000016356 COL20A1 1.25 2.07 0.016 0.037
ENSMUSG00000042821 SNAI1 1.26 2.53 0.017 0.039
ENSMUSG00000028163 NFKB1 1.27 6.41 0.000 0.000
ENSMUSG00000000303 CDH1 1.29 8.02 0.001 0.10
ENSMUSG00000019699 AKT3 1.32 5.14 0.000 0.000
ENSMUSG00000022676 SNAI2 1.33 2.98 0.006 0.016
ENSMUSG00000026104 STAT1 1.33 5.12 0.031 0.064
ENSMUSG00000002602 AXL 1.38 7.31 0.000 0.000
ENSMUSG00000026837 COL5A1 1.40 6.37 0.015 0.036
ENSMUSG00000048126 COL6A3 1.41 6.71 0.018 0.042
ENSMUSG00000007613 TGFBR1 1.42 7.06 0.000 0.000
ENSMUSG00000040033 STAT2 1.42 5.83 0.000 0.000
ENSMUSG00000026042 COL5A2 1.44 7.25 0.005 0.015
ENSMUSG00000035799 TWIST1 1.50 0.72 0.001 0.005
ENSMUSG00000029675 ELN 1.51 5.72 0.018 0.042
ENSMUSG00000025650 COL7A1 1.57 4.03 0.000 0.001
ENSMUSG00000032332 COL12A1 1.59 7.57 0.000 0.001
ENSMUSG00000031740 MMP2 1.60 5.97 0.000 0.001
ENSMUSG00000001119 COL6A1 1.60 6.43 0.004 0.013
ENSMUSG00000056174 COL8A2 1.60 2.33 0.005 0.016
ENSMUSG00000026043 COL3A1 1.60 9.07 0.022 0.048
ENSMUSG00000020241 COL6A2 1.61 5.96 0.006 0.018
ENSMUSG00000019899 LAMA2 1.63 6.05 0.000 0.000
ENSMUSG00000024304 CDH2 1.65 3.41 0.04 0.23
ENSMUSG00000028339 COL15A1 1.71 7.56 0.000 0.000
ENSMUSG00000049723 MMP12 1.87 3.84 0.001 0.005
ENSMUSG00000039462 COL10A1 3.92 0.24 0.001 0.002
(B)
ENSMUSG00000013584 ALDH1A2 1.27 5.62 0.001 0.002
ENSMUSG00000007888 CRLF1 1.34 3.46 0.009 0.023
ENSMUSG00000046179 E2F8 1.43 1.37 0.022 0.048
ENSMUSG00000033060 LMO7 1.21 6.62 0.002 0.008
ENSMUSG00000063450 SYNE2 1.25 8.79 0.021 0.046
ENSMUSG00000032232 CGNL1 1.28 8.79 0.000 0.000
ENSMUSG00000034427 MYO15B 1.27 6.78 0.010 0.026
ENSMUSG00000022708 ZBTB20 1.24 8.27 0.029 0.061
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kidneys, as reflected by mRNA abundances. A total of
1424 genes were significantly differentially expressed in
bemcentinib-treated animals compared to vehicle-treated
animals (n = 6 for each group) (Fig. 5A). Principal com-
ponent analysis (PCA) revealed that the ligation effect is
the dominant factor explaining the variance of the data
(principal component PC1), and the treatment effect
appears to be explained by the data variance in PC2).
Interestingly, the difference of the group mean of the
ligated and nonligated bemcentinib-treated kidneys is
smaller than the corresponding mean difference of the
vehicle-treated kidneys, suggesting a reduction in the liga-
tion effect due to bemcentinib treatment.
To further test the effect of ligation and treatment on
gene expression in the tissue, the expression values of 63
fibrosis-related genes were visualized in a PCA (Fig. 5B).
Besides the strong ligation effect (PC1), PC2 reveals that
the nonligated samples have a rather large variance but
do not segregate into the two treatment groups. The
ligated samples however have tendency of forming two
clusters according to their treatment group. This indicates
that the two groups separate from each other based on
the expression pattern of these fibrosis genes. Six genes of
this group were also present in the list of 1424 differen-
tially affected genes, such as Angiotensinogen (AGT),
Bone morphogenetic protein 7 (BMP7), Chemokine (C-C
motif) ligand 12 (CCL12), Collagen type III, alpha 1
(COL3A1), Matrix metalloproteinase 8 (MMP8), and
Plasminogen activator urokinase (PLAU).
Lower range of expression changes of genes
related to EMT, fibrosis, extracellular
matrix, MARGS and macrophage markers
following bemcentinib treatment
Five gene lists for EMT, fibrosis, extracellular matrix
(ECM), metzincins and related genes (MARGS) and
macrophage markers were extracted from the literature
and publicly available databases as described in Material
and Methods (Table S1). A randomly generated gene list
served as control. For EMT, fibrosis, ECM, macrophage
markers and MARGS, there was significantly less alter-
ation (“perturbation”) of gene expression in the bemcen-
tinib-treated group compared to the vehicle-treated
group, indicating that expression levels of genes involved
in these pathways were less changed. Results are summa-
rized in Figure 6.
Bemcentinib reduces F4/80+cell infiltration
and C-C motif Chemokine ligands in ligated
kidneys
In accordance with less perturbation of macrophage
markers in the bemcentinib group (Fig. 6), significantly
less F4/80 positive cells were stained in IHC in ligated
bemcentinib-treated compared to ligated vehicle-treated
kidneys after 15 days (19.5  6.9% in ligated bemcen-
tinib-treated, 33.5  8.9% in ligated vehicle-treated kid-
neys, P = 0.01, one-way ANOVA) (Fig. 2N–P).
Effect of bemcentinib
on ligated kidneys
(n = 1424)
Fibrosis genes
(n = 63)
L-Bem L-Bem
NL-Bem NL-Bem
NL-Veh
L-Veh L-Veh
NL-Veh
A B
Figure 5. Effect of bemcentinib treatment on gene expression after 15 days of ureteral obstruction. Principal component analysis (PCA) was
performed on expression data of genes with statistically relevant difference in expression pattern in ligated kidneys after bemcentinib or vehicle
treatment (A), and fibrosis-related genes (B). In both graphs, the influence of ligation is the largest contributing factor (PC1, in %), followed by
the effect of treatment (PC2, in %). In (A), the distance of the group mean centers of ligated and nonligated samples in PC1 is reduced from
76.5 for the vehicle-treated groups to 59.7 after the bemcentinib treatment, suggesting a reduction of the ligation effect due to bemcentinib
treatment. As visual aid, shaded density ellipses outline the probability of 90% of data laying within the contour. L = ligated, NL = nonligated,
Bem = bemcentinib-treated, and Veh = vehicle-treated.
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Combined treatment of bemcentinib plus ACEI also
yielded significantly less F4/80 positive cells in IHC but
again without additive effect compared to bemcentinib
alone (16.4  3.4% in ligated bemcentinib plus ACEI-
treated kidneys, P = 0.001, one-way ANOVA). ACEI
treatment alone did not alter F4/80 expression (Fig. 4F).
In a multiplex ELISA essay, treatment with bemcentinib
was found to reverse several cytokines that were induced
by the ureteral ligation. MCP1 (CCL2), MCP3 (CCL7),
MCP5 (CCL12), and TARC (CCL17) were significantly
less abundant in the lysates from ligated bemcentinib-
treated compared to ligated vehicle-treated kidneys (both
n = 5, MCP1 P = 0.001, MCP3 P = 0.034, MCP5
P = 0.028, TARC P = 0.008 and FGF P < 0.001, one-way
ANOVA). TARC (CCL17) was also significantly under-
represented in ligated bemcentinib-treated compared to
ligated ACEI-treated kidneys (TARC P = 0.004, one-way
ANOVA). These results reflect an anti-inflammatory effect
in the ligated kidneys by bemcentinib treatment com-
pared to the vehicle-treated controls – probably in
particular in the context of monocyte and macrophage-
related infiltrates (Fig. 7).
Bemcentinib treatment affects metabolic
pathways related to immune system and
cytokine secretion
Next, genome-wide transcriptional changes in UUO and
the impact of bemcentinib treatment were analyzed. First,
we performed transcriptome analysis of ligated compared
to nonligated vehicle-treated kidneys. Gene ontology anal-
ysis indicated differences in metabolic pathways mainly
related to mitochondria, which were down-regulated in
the ligated kidneys compared to the nonligated kidneys,
whereas metabolic pathways associated with EMT and
cytokine induction were up-regulated in the ligated kid-
neys compared to the nonligated controls (data not
shown). Furthermore, the gene ontology analysis compar-
ison of the ligated bemcentinib-treated compared to
ligated vehicle-treated kidneys, highlights that
Figure 6. Perturbation scores indicate reduction of ligation effect by bemcentinib treatment after 15 days of ureteral obstruction. Perturbation
scores as measures of extent of gene expression changes for six gene lists are presented. (A–F), decrease of perturbation scores in ligated
bemcentinib-treated kidneys applying one EMT (A), three fibrosis (B–D)related gene lists and one gene list with macrophage markers (E)
indicates an ameliorating effect of the treatment with bemcentinib on fibrosis development and inflammation in the context of macrophages.
(F) A random gene list serves as control for the analysis; its perturbation score difference remains statistically insignificant.
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bemcentinib affects metabolic pathways related to the
immune system and cytokine secretion, whose expression
was less in ligated bemcentinib-treated kidneys, and mito-
chondria-related pathways, whose expression was higher
in ligated bemcentinib-treated kidneys than in ligated
vehicle-treated kidneys (Fig. 8).
Renal function remains stable
Renal function was assessed by serum creatinine levels. As
expected in UUO, creatinine levels in the serum were not
significantly different in the vehicle-treated UUO mice
(16.4  4.7 lmol/L SD; n = 12) compared to the bem-
centinib-treated animals (17.9  4.0 lmol/L SD, n = 12).
These values are only slightly above normal values in
mice measured by HPLC (7–13 lmol/L) (Dunn et al.
2004; Palm and Lundblad 2005).
Discussion
In this study, we have analyzed the potential role of AXL
RTK in the progression of fibrosis in the setting of experi-
mental UUO in mice. The underlying study hypothesis
was that AXL RTK promotes renal fibrosis development.
Accordingly, AXL inhibition should have beneficial effects
on the renal architecture with less renal fibrosis develop-
ment. As a proof of concept, we have therefore subjected
male C57Bl/6 mice to UUO for fibrosis induction, which
was accompanied by exposure to either bemcentinib, to
ACEI as an established clinically used anti-fibrotic
approach, to bemcentinib plus ACEI, or to its vehicle
alone as a control during 7 or 15 days. To our knowl-
edge, this is the first study analyzing the effect of AXL
RTK inhibition by bemcentinib in UUO.
The UUO model is a well-established model of pro-
gressive renal fibrosis with rapid, consistent disease devel-
opment allowing sacrifice of animals and analysis after 1
or 2 weeks (Nagle et al. 1973; Chevalier et al. 2009).
Moreover, complete ureteral obstruction is a simple pro-
cedure with high reproducibility (Yang et al. 2010). The
extent of fibrosis after UUO is known to be dependent of
the strain and gender of adult mice. In these experiment,
we wanted to investigate the anti-fibrotic effect of bem-
centinib and have therefore chosen male C57Bl/6 mice,
that are known to develop fibrosis. Female mice and the
BALB/c strain are less prone to develop renal fibrosis fol-
lowing UUO (Puri et al. 2010; Cho et al. 2012; Hewitson
et al. 2016).
Furthermore, two recent studies have shown that selec-
tive depletion of SNAI1 and TWIST inhibits partial EMT
development, fibrosis generation and lowers TGFb pro-
duction in ligated kidneys after UUO in mice. Partial
EMT thus represents a key feature in UUO-induced fibro-
sis (Grande et al. 2015; Lovisa et al. 2015). In our analy-
ses, pair-wise comparison between ligated and nonligated
kidneys showed substantial increase in fibrosis,
MCP1 MCP3 MCP5
A B C
D E
TARC FGF
Bemcentinib Bemcentinib Bemcentinib
Bemcentinib Bemcentinib
Figure 7. Chemokines and FGF in ligated and nonligated kidneys after 15 days of ureteral obstruction in the presence or absence of
bemcentinib treatment. Protein abundance of MCP1 (CCL2) (A), MCP3 (CCL7) (B), MCP5 (CCL12) (C) and TARC (CCL17) (D) and FGF (E) as
measured by ELISA in ligated (L) and nonligated (NL) kidneys treated with vehicle, bemcentinib, angiotensin-converting enzyme inhibitor (ACEI)
or bemcentinib + ACEI. Error bars represent standard deviation.
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inflammation, and up-regulation of several EMT-related
markers including AXL. Taken together, UUO represents
an appropriate fibrosis model to investigate the role of
the AXL RTK pathway and AXL RTK inhibition in the
kidney.
The main endpoint of our study is fibrosis develop-
ment. There are different methods to quantify organ
fibrosis. Accumulation of collagen I is characteristic for
fibrosis development and is induced by TGFb (Zeisberg
et al. 2001; Zeisberg and Neilson 2010). Using SR staining
with conventional light microscopy, collagens I, III, and
IV are all stained red (Farris and Alpers 2014). aSMA is
present in activated myofibroblasts contributing to renal
fibrosis, accordingly, aSMA is a recognized marker of
renal fibrosis (Alpers et al. 1993; Chevalier et al. 2009;
Zeisberg and Neilson 2010; LeBleu et al. 2013). Another
method that reflects fibrosis development is to measure
Hyp, a nonproteinogenic amino acid, which especially
occurs in collagens, where it stabilizes its triple helix (Berg
and Prockop 1973). Hyp content of tissues thus corre-
spond to the total collagen content and this method is
used in different settings to quantify collagen deposition
in the context of fibrosis development, such as in the
UUO model (Sato et al. 2003; Lovisa et al. 2015). There-
fore, our analyses support reduced fibrosis development
by bemcentinib treatment after 15 days of obstruction, as
reflected by decreased staining intensities for SR staining,
as well as lower Hyp content. These results are also in line
with the respective mRNA sequencing data of fibrosis-
related gene expression. Furthermore, reduced mRNA
abundances of individual genes relevant for pathogenesis
of fibrosis were observed in the ligated bemcentinib-trea-
ted group, including Tgfb1, Tgfb1r1/2, Akt3, Elastin,
Laminin and Smad2/4 (Yang et al. 2010; Pellicoro et al.
2012; Genovese et al. 2014; Wang et al. 2015).
Further work has to be done to explain the observation
that CDH2 protein and mRNA levels were not signifi-
cantly altered by UUO or bemcentinib treatment. Never-
theless, it has been suggested that CDH1 and CDH2 are
regulated in a time-dependent manner during tubular
epithelial injury, and that their use as consistent EMT
markers during UUO is questionable (Yang and Liu 2001;
A
B
FC
FC
Figure 8. Gene ontology pathway analysis of murine mRNA from ligated bemcentinib and vehicle-treated kidneys after 15 days of ureteral
obstruction. Top 15 up- (A) and down- (B) regulated gene ontology pathways in ligated bemcentinib-treated kidneys compared to the ligated
vehicle-treated controls. FC = fold change. Treatment with bemcentinib leads to the up-regulation of pathways related to mitochondria (such
as mitochondrial electron transport, mitochondrial respiratory chain complex I assembly and biogenesis and inner mitochondrial membrane
organization as well as mitochondrial ATP synthesis coupled proton transport) (A) and down-regulation of pathways related to the immune
system (lymphocyte and leukocyte activation, cytokine production, immune system development and regulation of immune system processes
and response) (B).
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Docherty et al. 2009; Grande et al. 2015; Choi et al.
2016).
In SR staining but not in Hyp content measurement,
bemcentinib treatment leads to less fibrosis development
in ligated kidneys when compared to ACEI. Bemcentinib
plus ACEI, however, did not have an additive effect. Pre-
vious data showed that rats subjected to UUO for 5 days
and treated with ACEI displayed 52% reduction in fibro-
sis development as compared to the untreated control
(Moridaira et al. 2003). The difference in ACEI effect
might be due to the fact that our model goes beyond the
first 5 days of UUO, which has been reported to be the
inflammatory phase of the fibrosis process (Kuncio et al.
1991; Chevalier et al. 2009).
AXL RTK activation is reported to regulate different
cellular processes, including survival, proliferation, migra-
tion, invasion, angiogenesis, but also processes related to
the immune system, where AXL RTK dampens inflamma-
tion through different mechanisms such as reduced Toll-
like receptor-dependent inflammatory signaling and
reduced activation of natural killer cells (Graham et al.
2014; Gay et al. 2017). AXL RTK and its sole ligand,
GAS6, are overexpressed and activated in many human
cancers and correlate with increased invasiveness and
metastasis, EMT and drug resistance. Expression of AXL
is activated by EMT transcription factors, including
SNAI1/2 and AXL RTK activation itself promotes EMT
via TWIST and SNAI1/2 (Graham et al. 2014; Akalu et al.
2017; Gay et al. 2017). AXL RTK inhibition reverses EMT
in cancer cells and blocks acquired drug resistance to
RTK inhibitors (e.g. Sunitinib) and chemotherapy (Kor-
shunov 2012; Yu et al. 2015; Zhou et al. 2016). Based on
these findings, it is likely that the AXL RTK pathway
plays also a role in the pathogenesis of organ fibrosis and
we speculate that attenuated induction of (partial) EMT
is one mechanism that explains the reduced fibrosis devel-
opment by AXL RTK inhibition in UUO. This is reflected
by reduced staining for VIM and less activated aSMA-
positive myofibroblasts in ligated bemcentinib-treated
compared to ligated vehicle-treated kidneys and is further
supported by down-regulation of EMT-related genes, such
as Snai1/2, Twist, Stat1, Zeb1/2, Akt3 and Axl, and also
Tgfb and Smad2/4. The latter genes are involved in the
canonical pathway of TGFb, which is known to be one of
the main triggers of EMT (Lamouille et al. 2014; Nieto
et al. 2016). The perturbation score, a method to display
gene expression differences of multiple genes simultane-
ously, also supports smaller extent of expression changes
of EMT-related genes following bemcentinib treatment.
Emerging literature support a role for AXL in fibrosis
development and an antifibrotic and anti-inflammatory role
of the AXL inhibitor bemcentinib. A study on liver fibrosis
showed that AXL and GAS6 are required to induce
fibrogenesis by hepatic stellate cells; Accordingly, exposition
to bemcentinib reduced liver fibrosis in mice. In addition,
less recruitment of antigen presenting cells, particularly
macrophages, were detected as measured by F4/80. Less
inflammation was also demonstrated by lower expression of
chemokines (Barcena et al. 2015). AXL has also been seen to
be up-regulated in idiopathic lung fibrosis and bemcentinib
lead to a reduction in fibrosis development in two mouse
lung fibrosis models (Espindola et al. 2018). Recently, a
study using murine anti–GBM-induced renal fibrosis mod-
els, showed less inflammation with reduced expression of
cytokines and chemokines, and an improved renal function
upon bemcentinib treatment. Accordingly, a similar effect
was found in AXL knock out mice (Zhen et al. 2018).
The UUO model – compared to the anti–GBM-
induced renal fibrosis model in (Zhen et al. 2018) – is
not based on autoimmune and inflammatory mecha-
nisms. However, obstruction leads to interstitial inflam-
mation, predominantly by monocyte/macrophage
infiltration, already after 3 days and inflammation is seen
as an important component and driver of fibrosis devel-
opment in UUO (Chevalier et al. 2009; Lopez-Novoa and
Nieto 2009).
The observed reduction in inflammation following bem-
centinib treatment could possibly also contribute to the
attenuation of fibrosis development by bemcentinib in
UUO. This was reflected by markedly less F4/80 positive
cells and less activated myofibroblasts in ligated bemcen-
tinib-treated kidneys compared to the ligated vehicle-trea-
ted control. F4/80 is known to stain mostly macrophages,
which are important producers of TGFb (Docherty et al.
2006; Dos Anjos Cassado 2017). The lower expression of
chemokines, cytokines, and the lower degree of expression
changes of macrophage marker genes in the perturbation
score in ligated bemcentinib-treated tissues indicate
reduced inflammation in ligated kidneys after bemcentinib
treatment. Down-regulation of metabolic pathways related
to immune system and cytokine secretion in the ligated
bemcentinib-treated kidneys further support these findings.
Reasons why targeting AXL seems to reduce inflamma-
tion in our experiments (and also in experiments per-
formed in liver fibrosis (Barcena et al. 2015)), might be
reduced activation of myofibroblasts, which are proin-
flammatory cells, or also the sustained effects of MERTK,
namely efferocytosis and reduced T-cell activation.
MERTK is not affected by bemcentinib due to the high
selectivity of the compound to AXL as compared to
MERTK (Graham et al. 2014).
It remains to be further investigated, to which degree
the attenuated fibrosis development is a consequence of
the inhibition of (partial) EMT in renal tubular cells and
of inflammation, or a result of other mechanisms such as
direct effect on activated renal myofibroblasts.
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In another experiment, we initiated treatment with
bemcentinib on day 3 after ureteral ligation. Interestingly,
delaying bemcentinib treatment did not show reduced
fibrosis development after 15 days (data not shown). Rea-
sons for this outcome remain unclear and it requires fur-
ther investigation if, for example, a missing attenuation of
inflammation by bemcentinib within the first 3 days after
ureteral obstruction might play a role.
Taken together, the blockade of the AXL RTK pathway
reduces renal fibrosis development in the context of
UUO. Most likely the mechanisms are a decrease of (par-
tial) EMT induction and reduction in inflammatory
response. Therefore, the AXL RTK pathway could be rele-
vant for fibrosis development and progression in many
different forms of CKD such as diabetic nephropathy.
In the clinical context, CKD is defined as a reduced
renal function measured by glomerular filtration rate,
which is often accompanied by proteinuria. A limitation
of our study is that UUO is a unilateral model of
tubulointerstitial fibrosis without renal function as an
end point. Therefore, further experiments should
employ renal fibrosis models that enable functional
read-outs to investigate whether inhibition of fibrosis
progression by bemcentinib treatment leads to improved
glomerular filtration rate and reduced proteinuria. Fur-
thermore and in the future, a suitable AXL knockout
model and also proteomic analyses could be performed
to supplement our findings in the context of fibrosis
development and inflammation alteration by AXL and
AXL RTK inhibition.
Conclusion
The AXL RTK pathway is involved in the pathogenesis of
renal fibrosis in UUO and represents a novel and promis-
ing target for the pharmacologic prevention of fibrosis
development in CKD.
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